Related Experiment Video

Updated: May 18, 2026

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas
03:07

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas

Published on: November 11, 2025

Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists

Verena Benz1, Ulrich Kintscher, Anna Foryst-Ludwig

  • 1Charité-Universitätsmedizin Berlin, Berlin, Germany. verena.benz@charite.de

Handbook of Experimental Pharmacology
|October 3, 2012
PubMed

Insights

Sex influences obesity and Type 2 Diabetes Mellitus (T2DM) development. This review explores sex-specific differences in treating these metabolic disorders using peroxisome proliferator-activated receptor (PPAR) ligands, focusing on their molecular mechanisms.

Area of Science:

  • Metabolic disorders
  • Pharmacology
  • Endocrinology

Background:

  • Sex significantly impacts the development of obesity, Type 2 Diabetes Mellitus (T2DM), and dyslipidemia, yet the underlying molecular mechanisms remain unclear.
  • Peroxisome proliferator-activated receptors (PPARs) are crucial regulators of lipid and carbohydrate metabolism.
  • PPAR ligands, including thiazolidinediones (TZDs) and fibrates, are widely used to treat T2DM and dyslipidemia.

Purpose of the Study:

  • To review and discuss the distinct aspects of sex-specific differences in antiobesity treatment.
  • To elucidate the molecular mechanisms behind sex-specific responses to PPAR ligands.
  • To highlight the implications for therapeutic strategies in metabolic disorders.

Main Methods:

  • Literature review of studies investigating sex differences in metabolic disease development.
  • Analysis of research on PPAR agonists (PPARgamma and PPARalpha) and their effects.
  • Synthesis of current knowledge on PPAR-mediated gene regulation in a sex-specific context.

Main Results:

  • Sex-specific differences in obesity, T2DM, and dyslipidemia prevalence are well-established.
  • PPARs play a key role in regulating metabolic pathways, with potential sex-dependent actions.
  • Existing PPAR-based therapies may exhibit differential efficacy and side effects between sexes.

Conclusions:

  • Understanding sex-specific mechanisms is crucial for optimizing PPAR-based therapies.
  • Further research is needed to fully elucidate the molecular basis of sex differences in metabolic regulation.
  • Tailoring antiobesity and antidiabetic treatments based on sex could improve patient outcomes.

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...